Nektar Therapeutics (NKTR) Issues Encouraging Update on Etirinotecan Pego Combo in BRCA1-Deficient MX-1 Tumor Model
Tweet Send to a Friend
Nektar Therapeutics (Nasdaq: NKTR) announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol (NKTR-102) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
